CL2023000648A1 - Métodos para tratar enfermedades o afecciones mediadas por pde iv - Google Patents

Métodos para tratar enfermedades o afecciones mediadas por pde iv

Info

Publication number
CL2023000648A1
CL2023000648A1 CL2023000648A CL2023000648A CL2023000648A1 CL 2023000648 A1 CL2023000648 A1 CL 2023000648A1 CL 2023000648 A CL2023000648 A CL 2023000648A CL 2023000648 A CL2023000648 A CL 2023000648A CL 2023000648 A1 CL2023000648 A1 CL 2023000648A1
Authority
CL
Chile
Prior art keywords
pde
methods
treating diseases
conditions mediated
conditions
Prior art date
Application number
CL2023000648A
Other languages
English (en)
Spanish (es)
Inventor
Koprivica Vuk
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CL2023000648A1 publication Critical patent/CL2023000648A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2023000648A 2020-09-10 2023-03-07 Métodos para tratar enfermedades o afecciones mediadas por pde iv CL2023000648A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063076774P 2020-09-10 2020-09-10

Publications (1)

Publication Number Publication Date
CL2023000648A1 true CL2023000648A1 (es) 2023-10-13

Family

ID=78080507

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000648A CL2023000648A1 (es) 2020-09-10 2023-03-07 Métodos para tratar enfermedades o afecciones mediadas por pde iv

Country Status (12)

Country Link
US (1) US12622915B2 (enExample)
EP (1) EP4210674A1 (enExample)
JP (2) JP7826294B2 (enExample)
KR (1) KR20230066350A (enExample)
CN (1) CN116507336B (enExample)
AU (1) AU2021338837A1 (enExample)
BR (1) BR112023004214A2 (enExample)
CA (1) CA3191177A1 (enExample)
CL (1) CL2023000648A1 (enExample)
IL (1) IL300628A (enExample)
MX (1) MX2023002539A (enExample)
WO (1) WO2022056265A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025224045A1 (en) * 2024-02-22 2026-08-06 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0314392A (pt) 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
PL378245A1 (pl) 2003-01-09 2006-03-20 Astellas Pharma Inc. Pochodne pirolopirydazyny
WO2007142929A2 (en) 2006-05-31 2007-12-13 The University Of North Carolina At Chapel Hill Novel pde4 inhibitors
US8080563B2 (en) * 2006-07-07 2011-12-20 Kalypsys Bicyclic heteroaryl inhibitors of PDE4
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물
TWI845795B (zh) * 2019-12-05 2024-06-21 美商汎達製藥公司 眼用醫藥組合物

Also Published As

Publication number Publication date
AU2021338837A1 (en) 2023-04-06
WO2022056265A1 (en) 2022-03-17
JP2023541261A (ja) 2023-09-29
JP7826294B2 (ja) 2026-03-09
BR112023004214A2 (pt) 2023-04-11
CA3191177A1 (en) 2022-03-17
IL300628A (en) 2023-04-01
US20230364100A1 (en) 2023-11-16
KR20230066350A (ko) 2023-05-15
CN116507336A (zh) 2023-07-28
EP4210674A1 (en) 2023-07-19
JP2026102632A (ja) 2026-06-23
MX2023002539A (es) 2023-03-14
US12622915B2 (en) 2026-05-12
CN116507336B (zh) 2026-01-02

Similar Documents

Publication Publication Date Title
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
CO2021010415A2 (es) Inhibidor jak y método de preparación del mismo
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CL2023003758A1 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2021012105A (es) Compuestos de pirrol.
BR112013027241A2 (pt) "composto inibidor de rock, composição que o compreende e seus usos"
BR112022002107A2 (pt) Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
CO2021017202A2 (es) Compuestos tricíclicos
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CO2025004701A2 (es) Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
MX2025002817A (es) Compuestos para el tratamiento del cancer
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
JOP20240183A1 (ar) مثبطات بروتين رابط لإموباميل واستخداماتها
BR112023004214A2 (pt) Métodos de tratamento de doenças ou condições mediadas por pde iv
MX2022015532A (es) Inhibidores selectivos de hdac6 y usos de los mismos.
CL2021001093A1 (es) Compuestos, composiciones, y métodos para modular la actividad cdk9